Patrick G Enright bought $2.3M of Zenas BioPharma (ZBIO)
Executed Oct 9 2025, disclosed Oct 14 2025, 5 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 14 2025), the stock returned +35.5% (delay-adjusted); from the execution session (Oct 9 2025), +23.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Patrick G Enright (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Vera Therapeutics, Inc. (VERA). Across 3 priced purchase filings, the average 21-session return was +18.6% from execution and +20.1% from disclosure (delay-adjusted; derived). The largest single filing was $18.3M of MANE (1,075,000 sh across 2 lots, as filed), executed Feb 5.
Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→440,000 sh × $17.00
Exec Sep 16 2024
Filed Sep 16 2024 · 5:30 PM ET